Some Shareholders Question GSK CEO's Ability To Overhaul Marketing Ills
This article was originally published in PharmAsia News
Executive Summary
As GlaxoSmithKline continues to deal with bribery allegations in China, which came to light less than a year after it agreed to $3 billion in U.S. fines to settle marketing fraud charges, some shareholders are beginning to question the CEO's promised overhaul.